Kiniksa Pharmaceuticals L... (KNSA)
Kiniksa Pharmaceuticals Ltd. Statistics
Share Statistics
Kiniksa Pharmaceuticals Ltd. has 72.64M shares outstanding. The number of shares has increased by 2.25% in one year.
| Shares Outstanding | 72.64M |
| Shares Change (YoY) | 2.25% |
| Shares Change (QoQ) | 1.34% |
| Owned by Institutions (%) | 0.18% |
| Shares Floating | 69.46M |
| Failed to Deliver (FTD) Shares | 205 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 2.11M, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 2.11M |
| Short % of Shares Out | 2.92% |
| Short % of Float | 3.06% |
| Short Ratio (days to cover) | 4.5 |
Valuation Ratios
The PE ratio is -32.71 and the forward PE ratio is 28.69. Kiniksa Pharmaceuticals Ltd.'s PEG ratio is 0.08.
| PE Ratio | -32.71 |
| Forward PE | 28.69 |
| PS Ratio | 3.34 |
| Forward PS | 1.5 |
| PB Ratio | 3.22 |
| P/FCF Ratio | 55.59 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Kiniksa Pharmaceuticals Ltd. has an Enterprise Value (EV) of 1.13B.
| EV / Earnings | -26.23 |
| EV / Sales | 2.68 |
| EV / EBITDA | -24.84 |
| EV / EBIT | -24.84 |
| EV / FCF | 44.59 |
Financial Position
The company has a current ratio of 3.3, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.3 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.2 |
| Cash Flow / Debt | 2.61 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.1% and return on capital (ROIC) is -12.16%.
| Return on Equity (ROE) | -0.1% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -12.16% |
| Revenue Per Employee | $1,343,615.87 |
| Profits Per Employee | $-137,120.63 |
| Employee Count | 315 |
| Asset Turnover | 0.73 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 7.04M |
| Effective Tax Rate | -0.19 |
Stock Price Statistics
The stock price has increased by 18.4% in the last 52 weeks. The beta is 0.48, so Kiniksa Pharmaceuticals Ltd.'s price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | 18.4% |
| 50-Day Moving Average | 20.65 |
| 200-Day Moving Average | 22.35 |
| Relative Strength Index (RSI) | 63.18 |
| Average Volume (20 Days) | 595.65K |
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals Ltd. had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.6.
| Revenue | 423.24M |
| Gross Profit | 423.24M |
| Operating Income | -45.62M |
| Net Income | -43.19M |
| EBITDA | -45.62M |
| EBIT | -45.62M |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 183.58M in cash and 9.86M in debt, giving a net cash position of 173.73M.
| Cash & Cash Equivalents | 183.58M |
| Total Debt | 9.86M |
| Net Cash | 173.73M |
| Retained Earnings | -521.14M |
| Total Assets | 580.55M |
| Working Capital | 231.18M |
Cash Flow
In the last 12 months, operating cash flow was 25.69M and capital expenditures -277K, giving a free cash flow of 25.41M.
| Operating Cash Flow | 25.69M |
| Capital Expenditures | -277K |
| Free Cash Flow | 25.41M |
| FCF Per Share | 0.36 |
Margins
Gross margin is 100%, with operating and profit margins of -10.78% and -10.21%.
| Gross Margin | 100% |
| Operating Margin | -10.78% |
| Pretax Margin | -8.54% |
| Profit Margin | -10.21% |
| EBITDA Margin | -10.78% |
| EBIT Margin | -10.78% |
| FCF Margin | 6% |
Dividends & Yields
KNSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.57% |
| FCF Yield | 1.5% |
Analyst Forecast
The average price target for KNSA is $37.5, which is 60.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.5 |
| Price Target Difference | 60.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 6.78 |
| Piotroski F-Score | 4 |